Comprehensive Medical Weight Loss Denver
Here is something the obesity medicine community needed to hear at this year’s American Diabetes Association Scientific Sessions: <strong>28.3% average weight loss at 80 weeks</strong>. Not a rounding error in a 12-person pilot. 2,339 adults with obesity, Phase 3 data,…
There’s a moment in every obesity medicine career when a drug does something unexpected. At this year’s American Diabetes Association Scientific Sessions in New Orleans, survodutide did several unexpected things at once. The dual GLP-1/glucagon receptor agonist — developed by…
Here’s something I hear constantly from patients: “I can handle the side effects, but the every-week injection is what wears me down.” It’s a real barrier — and honestly, one of the main reasons people fall off GLP-1 therapy. Pfizer…
CVS Caremark’s GLP-1 Shake-Up: Big Changes for Denver Patients Good news if you have commercial insurance: CVS Caremark — one of the largest pharmacy benefit managers in the country — just made it significantly easier to get GLP-1 weight loss…
CVS Restores Zepbound Coverage — and Adds Eli Lilly’s New Obesity Pill to the Mix For nearly a year, millions of Americans with commercial insurance had a hole in their weight management options. One of the most effective medications on…
Retatrutide’s 28% Weight Loss Is Eye-Opening. But Is More Always Better? Eli Lilly dropped a bombshell earlier this month: their next-generation obesity drug retatrutide helped patients lose up to 28% of their body weight over 80 weeks in a Phase…
GLP-1 Medications Reduce Cancer Spread You already know GLP-1 medications help with weight loss. You might have heard they reduce heart attack and stroke risk. Here’s one you probably haven’t seen in the headlines yet: GLP-1s may also help prevent…
For years, the headline around obesity in America has been relentless growth. More people, higher BMI, more disease. The trajectory looked inevitable — up and to the right, year after year. That may finally be changing. New data from EPIC…
CVS just flipped the script on GLP-1 coverage — and if you’ve been stuck paying out of pocket because your plan dropped Zepbound, this matters. What’s changing: CVS Caremark, one of the nation’s largest pharmacy benefit managers, will restore coverage…
New research confirms what many of us in obesity medicine have suspected for years — GLP-1 drugs do more than help people lose weight. They protect the heart. — A massive review of more than 90,000 participants across 11 major…
